Crohn's Disease Clinical Trials in Orlando, Florida

13 studies are recruiting for crohn's disease in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Digestive And Liver Center Of Florida - Orlando /ID# 280924, Orlando, Florida

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   AdventHealth Orlando ( Site 5131), Orlando, Florida

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

3. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

   Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 month…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Endoscopic Research, Inc., Orlando, Florida

   Locations

   101 in total

   Run by

   Takeda

   See if you can join NCT06581328 on ClinicalTrials.gov

4. A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

   Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active C…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437, Orlando, Florida

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT05995353 on ClinicalTrials.gov

5. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

   The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual …

   Stage

   Phase 4

   Ages

   18 to 70

   Site

   Endoscopic Research Inc, Orlando, Florida

   Locations

   48 in total

   Run by

   Takeda

   See if you can join NCT06045754 on ClinicalTrials.gov

6. A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

   This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Endoscopic Research Inc, Orlando, Florida

   Locations

   225 in total

   Run by

   Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

   See if you can join NCT06226883 on ClinicalTrials.gov

7. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

   The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Orlando Health, Orlando, Florida

   Locations

   183 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937099 on ClinicalTrials.gov

8. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study i…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   AdventHealth (Florida Hospital) Medical Group, Orlando, Florida

   Locations

   190 in total

   Run by

   Takeda

   See if you can join NCT06233461 on ClinicalTrials.gov

9. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Orlando Health, Inc.-Site Number: 8400084, Orlando, Florida

   Locations

   301 in total

   Run by

   Sanofi

   See if you can join NCT07184931 on ClinicalTrials.gov

10. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

    Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Endoscopic Research, Inc. /ID# 267211, Orlando, Florida

    Locations

    255 in total

    Run by

    AbbVie

    See if you can join NCT06548542 on ClinicalTrials.gov

11. A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

    The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Diseas…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Orlando Health Ambulatory Care Center, Orlando, Florida

    Locations

    138 in total

    Run by

    Takeda

    See if you can join NCT06227910 on ClinicalTrials.gov

12. A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

    This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Investigational Site Number: 8400007, Orlando, Florida

    Locations

    66 in total

    Run by

    Sanofi

    See if you can join NCT06958536 on ClinicalTrials.gov

13. A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

    This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    Mirador Therapeutics Selected Site, Orlando, Florida

    Locations

    66 in total

    Run by

    Mirador Therapeutics, Inc.

    See if you can join NCT07113522 on ClinicalTrials.gov